Skip to main content

Share story

Science

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas Image: Primary
Bioptimus announced the launch of its Spatial Tissue Embedding Learning Atlas, known as STELA. The multinational spatial data generation initiative is anchored by partnerships with 10x Genomics and Broad Clinical Labs. STELA aims to profile up to 100,000 patient tissue specimens across the United States, Europe, and Asia. This represents approximately a 20-fold increase in scale over existing spatial biology atlases. The project will integrate spatial transcriptomics, pathology imaging, multi-omics data, and longitudinal clinical records. The data generated will serve as the backbone for M-Optimus, the multimodal and multiscale world model of biology developed by Bioptimus. Participating institutions will follow standardized protocols and gain access to rich spatial characterization and foundation model capabilities. Jean Philippe Vert, co-founder and chief executive officer of Bioptimus, said the initiative envisions patients contributing insights to better inform care for future patients. Serge Saxonov, chief executive officer and co-founder of 10x Genomics, said the datasets will allow researchers to connect underlying biology with disease outcomes. Niall Lennon, chief scientific officer of Broad Clinical Labs, said the collaboration pairs massive-scale data generation with uncompromising data quality.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Bioptimus, Lumentum and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.